Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|EA6183||ECOG-ACRIN||A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A041202||Alliance||A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|ANZGOG-0902-GOG-0274||GOG||A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A011801||Alliance||The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinb||Adult CIRB - Late Phase Emphasis||Available to Open|
|S2005||SWOG||A Phase II Randomized Study of Ibrutinib and Rituximab with or without Venetoclax in Previously Untreated Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|GOG-0252||GOG||A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian; Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): Bevacizumab (NSC #704865; IND #113912)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GU001||NRG||Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|S0521||SWOG||A Randomized Trial of Maintenance versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL); Phase III||Adult CIRB - Late Phase Emphasis||Completed|
|CALGB-10603||CALGB||A Phase III Randomized; Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-HN005||NRG||A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|